De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study

Pediatric Transplantation

Volumn 17, Issue 3, 2013, Pages 237-243

  Grushkin, Carl ^a   Mahan, John D ^b   Mange, Kevin C ^c   Hexham, J Mark ^c   Ettenger, Robert ^d  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

cyclosporine; everolimus; pediatric; rejection; renal transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN; EVEROLIMUS; GANCICLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACNE; ACUTE GRAFT REJECTION; ADOLESCENT; ARTHRALGIA; ARTICLE; BIOPSY; CHILD; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIARRHEA; FEMALE; FEVER; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; HEADACHE; HEMATURIA; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTICENTER STUDY; NAUSEA; PEDIATRIC SURGERY; PRESCHOOL CHILD; RHINORRHEA; SCHOOL CHILD; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ADOLESCENT; ADRENAL CORTEX HORMONES; BIOPSY; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; RESEARCH DESIGN; SIROLIMUS; TREATMENT OUTCOME;

EID: 84876695987     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12035     Document Type: Article

References (34)

1. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Annual Report. Available at: https://web.emmes.com/study/ped/ annlrept/Annual%20Report%20-2008.pdf (accessed March 19, 2012).
2. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C,. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997: 63: 39-47.
3. Staskewitz A, Kirste G, Tonshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: Results after 12 months of treatment. Transplantation 2001: 71: 638-644.
4. Otukesh H, Sharifian M, Basiri A, et al. Mycophenolate mofetil in pediatric renal transplantation. Transplant Proc 2005: 37: 3012-3015.
5. Jose M,; Caring for Australians with Renal Impairment (CARI). Calcineurin inhibitors in renal transplantation: Adverse effects. Nephrology 2007: 12: S66-S74.
6. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD,. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004: 78: 557-565.
7. Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M,. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: A reappraisal. Nephrol Dial Transplant 2007: 22: 2440-2448.
8. Khosroshahi HT, Asghari A, Estakhr R, Baiaz B, Ardalan MR, Shoja MM,. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients. Transplant Proc 2006: 38: 2077-2079.
9. Ikonen TS, Gummet JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000: 70: 969-975.
10. Schuurman J-J, Ringers J, Schuler W, Slingerland W, Jonker M,. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000: 69: 737-742.
11. Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE,. Suppression of acute rejection in allogeneic rat lung transplantation: A study for the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999: 18: 150-159.
12. Pape L, Ahlenstiel T, Ehrich JH, Offner G,. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine. Pediatr Transplant 2007: 11: 291-295.
13. Ibáñez JP, Monteverde ML, Diaz MA, Goldberg J, Turconi AF,. Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 2007: 11: 777-780.
14. Halim MA, Al-Otaibi T, Johny KV, et al. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: A single center experience. Transplant Proc 2009: 41: 1666-1670.
15. Chinnock TJ, Shankel T, Deming D, et al. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients. Pediatr Transplant 2011: 15: 746-749.
16. Behnke-Hall K, Bauer J, Thul J, et al. Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. Pediatr Transplant 2011: 15: 784-789.
17. Nielsen D, Briem-Richter A, Sornsakrin M, et al. The use of everolimus in pediatric liver transplant recipients: First experience in a single center. Pediatr Transplant 2011: 15: 510-514.
18. Kanzelmayer NK, Ahlenstiel T, Drube J, et al. Protocol biopsy-driven interventions after pediatric renal transplantation. Pediatr Transplant 2010: 14: 1012-1018.
19. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de novo renal transplant patients. Transplantation 2003: 75: 2082-2085.
20. Ettenger R, Hoyer P-F, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant 2008: 12: 456-463.
21. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year Phase II, randomized, multicenter, open-label study. Transplantation 2004: 78: 1332-1340.
22. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010: 10: 1401-1413.
23. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose cyclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010: 10: 2349-2354.
24. Pape L, Lehner F, Blume C, Ahlenstiel T,. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011: 92: 658-662.
25. Schwartz GJ, Gauthier B,. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985: 106: 522-526.
26. Schwartz GJ, Feld LG, Langford DJ,. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984: 104: 849-854.
27. Ettenger RB, Grimm EM,. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001: 38 (Suppl 2): S22-S28.
28. Pengel LH, Liu LQ, Morris PJ,. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials Transpl Int 2011: 24: 1216-1230.
29. Benfield MR, Bartosh S, Ikle E, et al. A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010: 10: 81-88.
30. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008: 8: 984-989.
31. Delucchi A, Valenzuela M, Lillo AM, et al. Early steroid withdrawal in pediatric renal transplant: Five years of follow-up. Pediatr Nephrol 2011: 26: 2235-2244.
32. Koukourgianni F, Harambat J, Ranchin B, et al. Malignancy incidence after renal transplantation in children: A 20-year single-centre experience. Nephrol Dial Transplant 2010: 25: 611-616.
33. Olaitan OK, Zimmermann JA, Shields WP, et al. Long-term outcome of intensive initial immunosuppression protocol in pediatric deceased donor renal transplantation. Pediatr Transplant 2010: 14: 87-92.
34. Pascual J,. Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007: 22 (Suppl 1): i27-i35.